While the pace of dealmaking is accelerating, the unique qualities of cell and gene therapies require dealmakers to consider innovative strategies to optimize returns and reduce risk. Lev Gerlovin and co-author Pascale Diesel analyze and compare deal strategies in this European Pharmaceutical Manufacturer article.
The authors conducted an analysis of more than 30 deals executed in the cell and gene therapy sector recently and compared them to deals executed for monoclonal antibodies (mAbs) between 1999-2013. Emerging cell and gene therapies are often considered “magic bullets” in the treatment of many serious diseases – a claim that was applied to many mAbs when they were first introduced to the market about 20 to 25 years ago – and the level of interest in deal-making for these therapies is a reflection of the level of optimism companies have regarding their clinical and commercial potential. Findings from our analysis show that the pace of deal-making in cell and gene therapy is faster and occurring much earlier in the drug development process compared to deals seen in the past for breakthrough therapies including mAbs.
The authors acknowledge the contributions of Súil Collins and Alex David.
To read the entire article, click the link below.
How pharma companies are shifting deal strategies for cell and gene therapies
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...